Extracellular matrix alterations in inflammatory skin diseases: emerging biomarkers and clinical implications
Authors:
- Helena PortHPHelena Port
- Matej AndelicMAMatej Andelic
- Alexander NyströmANAlexander Nyström
- Aleksander Moldt HaackAHAleksander Moldt Haack
- Konstantinos KalogeropoulosKKKonstantinos Kalogeropoulos
- Valdemar Wendelboe NielsenVNValdemar Wendelboe Nielsen
- Antonius Pieter Van Den HeuvelAHAntonius Pieter Van Den Heuvel
- Asger Reinstrup BihletABAsger Reinstrup Bihlet
- Simon Francis ThomsenSTSimon Francis Thomsen
- Signe Holm NielsenSigne Holm Nielsen
Open Access
- 9 July 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (11) , 2118-2132
Abstract
The interaction among extracellular matrix (ECM) components (proteoglycans, elastin, laminins, collagens and metalloproteinases) is important for maintaining homeostasis of the skin. However, in chronic inflammatory diseases, tissue homeostasis is disrupted by having an uncontrolled remodelling of the ECM, resulting in an imbalance of its composition and functionality. In these pathologies, there is a dysregulation of the immune system characterized by recurrent itching, pain and inflammation in affected areas of the skin. Three of the most common inflammatory skin diseases are hidradenitis suppurativa, psoriasis and atopic dermatitis, with worldwide prevalence of 1%, 3% and 15%, respectively. The shared pathological characteristic for these diseases is an altered skin tissue structure, characterized by an excessive remodelling of ECM proteins. Despite well-documented evidence of ECM alterations in these pathologies, biomarkers reflecting ECM remodelling to aid drug development and potential treatment targets have been overlooked. There is therefore an unmet need to develop biomarkers for predicting outcomes and selecting treatment for individual patients. This review focuses on ECM dysregulation in inflammatory skin diseases, with a focus on how biomarkers can predict outcomes and monitor drug efficacy.Keywords
This publication has 175 references indexed in Scilit:
- Targeting inflammation with collagenClinical and Translational Medicine, 2022
- Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis SuppurativaJAMA Dermatology, 2022
- Pathophysiology, Clinical Presentation, and Treatment of PsoriasisJAMA, 2020
- Isolation and Culture of Human Dermal Fibroblasts2019
- Atopic Dermatitis: Pathophysiology2017
- Biomarker Development in Chronic Inflammatory Diseases2017
- Transition from inflammation to proliferation: a critical step during wound healingCellular and Molecular Life Sciences, 2016
- Lumican, a small leucine‐rich proteoglycanIUBMB Life, 2008
- Increased collagen synthesis in psoriasis in vivoArchives of Dermatological Research, 1995
- T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted productsEuropean Journal of Immunology, 1994